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INTRODUCTION 
Non-steroidal anti-inflammatory drugs 
(NSAIDs) are one of the most commonly prescribed 
1medication.  The gastrointestinal tract and kidneys 
are important targets of clinical events associated 
2with the use of NSAIDs.  Selective COX-2 
inhibitors have minimal gastrointestinal side effects. 
However, the newer NSAIDs also has nephrotoxic 
1effects remain as nonselective NSAIDs.  
The kidneys are the major organ for drug 
excretion, so that the renal arterioles and glomerular 
capillaries are especially vulnerable to the effects of 
3drugs.  The spectrum of NSAID-induced 
nephrotoxicity includes acute tubular necrosis, acute 
tubulointerstitial nephritis, glomerulonephritis, 
renal papillary necrosis, chronic renal failure, salt 
and water  retent ion,  hypertension,  and 
1hyperkalemia.  
Among the various clinical complications, 
the effects on the kidney are probably the most 
4common and severe due to the use of NSAIDs.  Fifty 
million US citizens report NSAIDs use, and it has 
been estimated that 500.000 – 2,5 million people 
will develop NSAID nephrotoxicity in the US 
5annually.  It has been reported that 37% of drug-
associated acute renal failure is associated with the 
use of NSAIDs, and NSAID-induced acute renal 
failure accounts for 7% of overall cases of acute 
4renal failure.  
This review discusses the NSAIDs, 
mechanisms and clinical manifestations of NSAID-
induced renal impairment and some NSAID options 
that can be used in patients with renal failure. 
NSAIDs 
NSAIDs have their origin in the extracts of 
salicylate-containing plants, in particular were 
known for their antipyretic, analgesic and anti-
6inflammatory properties.  NSAIDs exerts anti-
inflammatory, analgesic and anti-pyretic effects 
through the suppression of prostaglandin (PG), by 
inhibiting the enzyme cyclooxygenase (COX). Two 
isoforms of this enzyme COX-1 and COX-2 are 
known to exist. Nonselective NSAIDs inhibit both 
2COX-1 and COX-2.  Selective NSAIDs (COX-2 
selective inhibitors) inhibiting only the COX-2 
7isoform.  
Pharmacokinetics of NSAIDs 
Most NSAIDs are organic acids and are well 
absorbed in the gastrointestinal tract without 
substantial decreases in their bioavaibility with the 
highest concentration 1 to 4 hours. NSAIDs 
undergoes metabolism in the liver and are excreted 
through the kidneys. NSAIDs is largely bound to 
albumin in the blood (95% -99%) and have low 
volume of distribution. NSAIDs may across the 
blood brain barrier depending on lipid solubility. 
The half-life varies for different NSAIDs, but are 
generally divided into short (<6 hours) and long (>6 
hours). Mechanisms of action and side effects of 
NSAIDs for each patient varies depending on the 
type of NSAID used. This difference arises because 
of differences in the absorption, distribution and 
8metabolism in the human body.  
Physiological Role of Prostaglandins in the 
Kidney 
Prostaglandins were first described by 
Goldblatt as substances produced by the prostate 
gland and contained in the seminal fluid, with 
antihypertensive properties. Subsequently, it was 
shown that prostaglandins are produced by a large 
variety of cells in the human body. During the 
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biosynthesis of prostaglandins, cyclooxygenase 
(COX or prostaglandin H synthase) catalyses the 
conversion of arachidonic acid to prostaglandin 
endoperoxidases, prostaglandin G  (PGG ) and then 2 2
PGH . PGH  is the precursor of the biologically 2 2
active prostaglandins and thromboxanes. PGH  is 2
then isomerized into various prostanoids such as 
thromboxane A  (TXA ), prostacyclin (PGI ), PGD , 2 2 2 2
6PGE  and PGF .  2 2a
6Figure 1. The arachidonic acid cascade  
Prostaglandins regulate a wide variety of 
renal functions. Prostaglandins maintain renal blood 
flow and glomerular filtration rate (GFR), especially 
in fluid depleted states. PGE  is considered to be 2
mainly a tubular PG and PGI  a vascular PG. 2
However, renal arterioles, tubules, medullary 
interstitial cells and mesangial cells are able to 
produce both PGE  and PGI  The physiological 2 2.
effects of PG  are mediated through the four G-2
protein-coupled transmembrane prostaglandin 
2receptors EP  EP  EP  EP .  Locally synthesized 1, 2, 3, 4
prostaglandins PGI  (prostacyclin), PGE  and PGD  2 2 2
cause vascular dilatation, diminish vascular 
resistance and enhance renal perfusion with 
redistribution of blood flow from the renal cortex to 
nephrons in the juxta-medullary region. PGE  and 2
PGF  cause diuresis and natriuresis by inhibiting the 2a
transport of sodium and chloride in the thick 
ascending limb of loop of Henle and the collecting 
ducts. PGE1 tends to counteract the action of 
1antidiuretic hormone (vasopressin).  
In volume contracted states, renin-
angiotensin-aldosterone axis are stimulated with 
increased renin, angiotensin II, and aldosterone 
production resulting in renal vasoconstriction and 
increased sodium and chloride reabsorption. There 
is increased sympathetic outflow, which further 
increases the vascular tone. In that setting, 
prostaglandins provide compensatory vasodilation 
of renal vascular bed and ensure adequate renal 
blood supply. PGE  PGD  and prostacyclin cause 2, 2
vasodilation by depressing norepinephrine release. 
PGE  antagonizes the vasoconstrictive action of 2
1,7angiotensin II on afferent arterioles. 
NSAID-induced renal impairment can be 
grouped according to their effects on prostaglandin 
PGE  and PGI  When the production of PGI  is 2 2. 2
blocked, hyperkalemia and acute renal failure can 
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result. The effect of blocking the production of PGE  2
may include peripheral edema, increased blood 
pressure, weight gain and through rare, congestive 
7heart failure.  
There are two kinds of COX enzymes, 
COX-1 and COX-2. Both of these proteins have the 
same molecular weight, but are structurally distinct 
in their substrate binding sites, which are smaller in 
COX-1 than in COX-2. The active site of COX lies 
in a narrow hydrophilic tunnel composed of an 
active inner site and protected by an outer area that is 
made up of three á helices. NSAIDs attaches to these 
outer helices and temporarily prevent the passage of 
arachidonic acid from reaching the active site and 
6triggering the production of prostaglandins.  
COX-1 is constitutively expressed in most 
cells and is involved in physiological processes. The 
COX-1 expression is also found in fetal and 
amniotic cells, uterine epithelium in early pregnancy 
and in the central nervous system. COX-2 was 
considered to be induced by inflammation and the 
presence of proinflammatory cytokines and 
6mitogens.  In general, COX-1 functions in the 
control of renal hemodynamics and glomerular 
filtration rate; COX-2 functions affect salt and water 
excretion, although there is some overlap. This 
separation of COX-mediated functions in the kidney 
is based in part on the physiologic / anatomic 
7distribution of COX-1 compared to COX-2.  
Blockade of either or both of these enzymes can 
2have different effects on renal function. 
Risk Factors of NSAID-induced Renal Side 
Effects
There is an increased risk of developing 
renal damage in patients who regularly consume 
NSAIDs. This risk increases with advanced age and 
other comorbidities. Age-related changes in renal 
function predispose to nephrotoxicity, especially 
when there is a decrease GFR, decreased renal blood 
flow and increased renal vascular resistance, 
dehydration or impaired liver function. The risk of 
renal dysfunction is further enhanced by the 
presence of sepsis, multiple organ dysfunction, and 
critical illness in general. Recent analysis of general 
practice database in the United Kingdom, current 
users of NSAIDs had a relative risk of acute renal 
failure of 3.2 (95% confidence interval, 1.8-5.8). 
This risk increased with comorbid illness and in 
particular it increased dramatically to 11.6 (95% 
confidence interval, 4.2-32.2) when concomitant 
4diuretics were being taken. 
4Table 1. Risk Factors for NSAID-induced Renal Side Effects in the Elderly Population  
Risk Factors for NSAID-Induced Renal Side Effects in the Elderly Population
Age-related changes in renal function  
Decreased renal functional reserve  Decreased glomerular filtration rate
 Decreased total renal blood flow
 Increased renal vascular resistance
 Diabetes mellitus
 Altered pharmacokinetics
 Increased free drug concentration
 Dehydration
 
Reduced drug distribution volume
 
Hypoalbuminemia
 
Decreased elimination of the drug via alternative pathways
 
Interaction with other drugs
 
Diuretics
ACE inhibitors
Beta blockers
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Mechanisms of Drug-induced Acute Kidney 
Injury 
There are several mechanisms of drug-
i n d u c e d  a c u t e  k i d n e y  i n j u r y  i n c l u d e  
vasoconstriction, altered intraglomerular 
hemodynamics, tubular cell toxicity, interstitial 
nephritis, crystal deposition, drug-induced 
thrombotic microangiopathy, osmotic nephrosis, 
and rhabdomyolysis. The mechanisms associated 
with NSAIDs use was altered intraglomerular 
hemodynamic and interstitial nephritis. 
1. Altered Intraglomerular Hemodynamics 
Altered intraglomerular hemodynamics are 
responsible for the decline in renal function seen 
with NSAIDs, angiotensin converting enzyme 
inhibitors (ACEI), angiotensin receptor blockers 
(ARB). In patients with hemodynamic instability 
and volume depletion, renal perfusion becomes 
prostaglandin-dependent. Renal dysfunction that 
accompanies antihypertensive therapy is a result of 
excessive lowering of blood pressure. ACEI and 
ARB are more commonly associated with this 
c o m p l i c a t i o n  b e c a u s e  a n y  d e c l i n e  i n  
intraglomerular pressure due to blood pressure 
lowering will be exaggerated by concomitant 
vasodilation of the efferent arteriole. And even 
without a decline in blood pressure, the decrease of 
efferent resistance may result in a lower GFR in 
patients where constriction of the efferent arteriole 
serves to minimize the decline in GFR such as in 
patients with absolute or effective reduction in 
intravascular volume, in patients with obstructive 
renal vascular disease or in patients receiving drugs 
9associated with afferent vasoconstriction. 
2. Interstitial Nephritis 
Acute interstitial nephritis defines a pattern 
of renal injury usually associated with an abrupt 
deterioration in renal function characterized 
histopathologically by inflammation and edema of 
10the renal interstitium.  It occurs on the allergic basis 
9in an idiosyncratic and nondose-dependent manner.  
The nature of this disorder is usually diagnosed 
4through a kidney biopsy.  Acute interstitial nephritis 
has become an important cause of acute renal failure 
due to the increasing use of antibiotics and other 
medications such as NSAIDs that may induce an 
10allergic response in the interstitium.  Interstitial 
nephritis can occur in association with NSAIDs due 
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to allergic reaction, direct cellular toxicity, 
alteration of metabolic pathways and possibly 
obstruction. These complex and multifactorial 
mechanisms may also combine with hemodynamic 
perturbations. In some cases, the damage becomes 
4extensive, leading to papillary necrosis. 
The onset after drug exposure ranges from 3 
to 5 days with a second exposure up to several 
9weeks with the first exposure.  Acute interstitial 
nephritis symptoms develop within 3 weeks after 
the inciting drug in about 80% of patients. The 
typical presentation is a sudden impairment in renal 
function, mild proteinuria (<1g/day), abnormal 
urinalysis, flank pain, normal blood pressure and no 
edema. Hematuria and pyuria are present in 
approximately one-half of patients, with leukocyte 
casts. Occasionally, patients have a low fractional 
11excretion of sodium.   
Manifestations of NSAID-induced Kidney 
Disorders 
        1. Na t r ium Reten t ion ,  Edema,  and  
Hypertension 
The use of non-selective NSAIDs or 
selective NSAIDs may be complicated by the 
development of significant sodium retention, 
edema, congestive heart failure, and hypertension. 
COX-2 inhibition likely promotes salt retention via 
multiple mechanisms. Reduce GFR may limit the 
filtered sodium load and salt excretion. In addition, 
PGE  directly inhibits sodium absorption in the 2
thick ascending limb and collecting duct. COX-2 
inhibitors decrease renal PGE  production and 2
thereby may enhance renal sodium retention. 
Finally, reduction in renal medullary blood flow by 
inhibition of vasodilators prostanoid may 
significantly reduce renal salt excretion and 
promote the development of edema and 
12hypertension. 
        2. Hyperkalemia 
N o n - s e l e c t i v e  N S A I D s  c a u s e  
hyperkalemia due to suppression of the renin / 
aldosterone axis. Both decreased GFR and 
inhibition of renal renin release may compromise 
renal potassium excretion. The study in patients 
with dietary salt restriction demonstrated that COX-
2 selective inhibitor (either rofecoxib or celecoxib) 
Tiwi Charisma, et al
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12decreased urinary potassium excretion.  Patients  
with diabetes mellitus, CKD or both, hyperkalemia 
may develop after administration of NSAIDs. Other 
aggravating factors are simultaneous consumption 
of potassium-sparing diuretics, ACEI or ARB, and 
beta blockers. In these circumstances, hyperkalemia 
may be accompanied by a mild metabolic acidosis 
4and a deterioration in renal function. 
        3. Papillary Necrosis 
Both acute and sub acute forms of papillary 
necrosis has been observed with NSAIDs use. Acute 
renal papillary injury associated with NSAID 
occurs more likely in the setting of dehydration. 
Long-term use of NSAIDs has been associated with 
papillary necrosis and progressive renal structural 
and functional deterioration much like the 
syndrome of analgesic nephropathy. Observational 
studies indicate that renal medullary interstitial cells 
are the early target of injury in analgesic 
12nephropathy. 
Analgesic nephropathy is a slowly 
progressive chronic kidney disease resulting from 
daily use for many years of preparations containing 
at  least  two analgesics  (e .g. ,  Aspir in,  
acetaminophen) in combination with central-acting 
dependence-inducing substances, such as caffeine, 
codeine, and / or barbiturates. Analgesic 
nephropathy is characterized by capillary sclerosis, 
renal cortical atrophy, chronic interstitial nephritis 
and / or papillary sclerosis / necrosis / calcifications. 
In some patients with analgesic nephropathy, the 
uroepithelia can develop transitional cell 
carcinoma. Analgesic nephropathy can be 
accurately diagnosed or excluded by CT-scan 
2without contrast media. 
        4. Acute Renal Failure 
NSAIDs may cause acute renal failure due 
to acute interstitial nephritis as a result of allergic 
hypersensitivity reaction few days after the 
initiation of NSAID therapy. In this case, kidney 
function usually recovers when NSAIDs are 
discontinued. Long-term NSAIDs use may result in 
chronic interstitial nephritis with interstitial fibrosis 
2and chronic renal dysfunction.  
Acute renal failure is generally considered 
to be a result of altered intrarenal microcirculation 
and glomerular filtration secondary to the inability 
to produce beneficial endogenous prostanoids when 
the kidneys are dependent on them for normal 
function. Recent reports suggest that like the 
traditional, non-selective NSAIDs, COX-2 
selective NSAIDs will also reduce glomerular 
12filtration. 
There is some evidence to support an 
increased incidence of adverse effects with 
increased doses of selective and non-selective 
NSAIDs. Some medications, such as ACEI, ARB 
and beta blockers may increase NSAID-related 
renal complications. The high acute dose of 
NSAIDs has been implicated as causes of acute 
renal failure, particularly in the elderly. Some 
reported cases of acute renal failure after initiation 
of NSAIDs therapy include apparent in healthy 
subjects. Case reports have  documented acute renal 
failure in association with both celecoxib and 
rofecoxib. Of 1799 frail elderly patients 
hospitalized with community-acquired acute renal 
failure, 18.1% were current users of prescribed 
NSAIDs. In this study, a strong dose-dependent 
increase of risk for acute renal failure was observed 
2in 35% subjects taking ibuprofen. 
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        5. Nephrotic Syndrome 
Nephrotic syndrome typically occurs in 
patients who are chronically taking NSAIDs within 
a period of several months. The renal pathology is 
usually consistent with minimal change disease 
with foot process fusion of glomerular podocytes, 
but membranous nephropathy has also been 
reported. Typically, nephrotic syndrome occurs 
together with interstitial nephritis. Nephrotic 
syndrome without interstitial nephritis may occur, 
as well as immune-complex glomerulopathy, in a 
small subset of patients receiving NSAIDs. It 
remains uncertain whether this syndrome results 
from mechanism-based cyclooxygenase inhibition 
by these drugs, an idiosyncratic immune drug 
12reaction or a combination of both. 
6. Renal Dysgenesis 
Reports of renal dysgenesis and 
oligohydramnions in offspring of women 
administered non-selective NSAIDs during the 
third trimester of pregnancy have implicated 
prostaglandins in the process of normal renal 
development. A similar syndrome of renal 
dysgenesis has been reported in mice with targeted 
disruption of the COX-2 gene, as well as mice 
treated with the specific COX-2 inhibitor. A report 
of renal dysgenesis in the infant of a woman 
exposed to the COX-2 selective inhibitor 
nimesulide suggests COX-2 also play a role in renal 
12development in humans. 
13Table 2. Predisposing factors for NSAID-Induced Acute Renal Failure
Predisposing Factors for NSAID-Induced Acute Renal Failure
Decreased effective blood volume (eg, from congestive heart failure, cirrhosis, nephrotic 
syndrome, anesthesia, shock)
 
Decreased absolute volume (eg, from hemorrhage, sodium and water depletion)  
Acute renal failure 
Chronic kidney disease 
Medications (eg, angiotensin -converting enzyme inhibitor, angiotensin receptor blocker, 
aldosterone receptor antagonist, diuretics, cyclosporine)  
Renal transplantation
 
Advanced age
The intrarenal expression of COX-2 in the 
developing kidney peaks in mouse at post-natal day 
4 and in the rat in the second post-natal week. It has 
not yet been determined if a similar pattern of COX-
122 is seen in humans.  COX-2 is expressed 
continuously not only in the adults but also in the 
fetal kidney. COX-2 dependent PG formation is 
necessary for normal renal development. 
Prostanoids or other products resulting from COX-2 
activity in the macula densa may act in a paracrine 
manner to influence glomerular development. Mice 
deficient COX-2 exhibit renal dysgenesis. In 
contrast, research on gene showed that COX-1 
disruption does not interfere with normal renal 
development. Administration of a COX-2 selective 
inhibitors during pregnancy significantly impaired 
development of renal cortex and reduced 
glomerular diameter in mice, while administration 
of a COX-1 selective inhibitor did not affect renal 
2development.  
       7. Worsening of Chronic Kidney Disease 
(Acute on Chronic Renal Failure) 
The use of NSAIDs is often associated with 
worsening of mild to moderate chronic kidney 
disease (CKD), with a significant reduction of GFR 
and the evolution of CKD toward more advanced 
stages. Direct toxicity to the tubules is manifested 
by loss of polarity, loss of tight junctions, loss of cell 
substrate adhesion, exfoliation of viable cells from 
the tubular basement membrane and aberrant renal 
Tiwi Charisma, et al
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cell-cell adhesion. Further damage may contribute 
to altered gene expression, cellular differentiation 
and lethal injury such as necrosis or apoptosis. 
Tubular necrosis is characterized by severe 
depletion of cellular stores of adenosine 
triphosphate, reduced activity of membrane 
transport pumps, cell swelling, increase in 
intracellular free calcium, activation of 
phospholipases and proteases, depletion of glycine 
4and plasma and subcellular membrane injury.  
Patients at risk for acute kidney injury by 
advanced age or dehydration, may experience 
abrupt worsening of CKD with reduction of 
glomerular filtration and acute-on-chronic renal 
failure. Additional risk factors include congestive 
heart failure, alcohol abuse, and chronic use of 
4diuretics. 
Research on the relationship of regular use 
analgesics such as acetaminophen, aspirin, or 
NSAIDs with chronic renal dysfunction showed 
different results. A case-control study reported on 2-
fold increased risk of end-stage renal disease 
among individuals with lifetime use of more than 
1000 acetaminophen tablets and 8-fold increased 
risk among those with a lifetime cumulative dose of 
more than 5000 tablets NSAIDs. In contrast, 
multivariable analysis performed in a total 11,032 
healthy men demonstrated that the relative risk of 
elevated creatinine levels associated with intake of 
in 2500 tablets or more analgesics were 0.83 for 
acetaminophen, 0.98 for aspirin, and 1.07 for other 
NSAIDs. There was no association observed 
between analgesic use and reduced creatinine 
clearance. A case-control study found a greater than 
2-fold increased risk of newly diagnosed chronic 
renal insufficiency for regular users of 
acetaminophen or aspirin. In the Nurse's Health 
study, acetaminophen use was associated with an 
increased risk of GFR decline in 11 years, but not on 
the use of aspirin and NSAIDs. In contrast, any 
case-control studies found an association between 
2NSAIDs and the risk of chronic renal dysfunction. 
Gooch et al, determined the association 
between NSAID use and progression of CKD in an 
elderly community-based cohort. A total of 10,184 
subjects (average age 76 years) were followed for a 
median 2.75 years. High-dose NSAIDs users were 
associated with an increased risk for rapid CKD 
progression among subjects with a baseline mean 
2GFR between 60 and 89 ml/min/1.73 m  without 
risk differential between selective and non-selective 
2NSAIDs users.  Many epidemiological studies 
have linked NSAIDs use and progression of CKD, 
but the risks of NSAIDs in patients with CKD so far 
supported only by consensus and theoretical effect, 
14remain less clearly established by the evidence. 
Analgesic Therapy in Patients with CKD 
Although primary care and general 
medicine textbooks and clinical practice guidelines 
recommend avoidance of NSAIDs for most CKD 
patients, clinicians should consider the risks and 
benefits on a case-by-case basis, with determination 
and consideration of their patients's CKD status and 
14the use of NSAIDs.
NSAIDs should be avoided or given 
cautiously in patients with stage 4 or higher CKD 
(GFR < 30mL/min). Pain management with 
NSAIDs in patients with CKD should be based on 
precise indications and given the limited time. 
NSAIDs should be initiated at the lowest effective 
dose and adjusted for those drugs that are excreted 
mainly by the kidneys as well as strict monitoring of 
blood pressure, body weight (as a marker of edema 
13formation), renal function and electrolytes.  
        1. Non-selective NSAIDs 
NSAIDs are used as primary or adjuvant 
therapy at all steps of the WHO analgesic ladder. 
There is no evidence that they are more effective for 
certain types of pain rather than others. A meta-
analysis of non-selective NSAIDs found no 
evidence for the analgesic superiority of one 
NSAID over others, but the side effect profiles can 
13differ significantly.  
        2. Aspirin and NSAIDs 
In therapeutic doses, aspirin does not 
impair renal function in patients with normal renal 
function. But as well as other types of NSAIDs, 
patients with CKD may have a transient decrement 
in renal function with aspirin dosages above 325 mg 
/ day. Aspirin and NSAIDs should not be merged 
because they may reduce GFR. NSAIDs may be 
deleterious to the cardioprotective effects of aspirin. 
Regular aspirin use does not influence hypertension 
or increase risk for CKD when given in 
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recommended doses for the prevention of 
cardiovascular events. Aspirin should be avoided in 
patients with acute glomerulonephritis, cirrhosis 
with ascites, and children with congestive heart 
failure to avoid potential nephrotoxicity. In all other 
conditions are accompanied with CKD, risk versus 
benefit should be assessed. If aspirin therapy should 
be given routinely, careful monitoring of renal 
13function should be performed at regular interval.  
        3. Selective COX-2 Inhibitors 
CKD patients are at higher risk for adverse 
gastrointestinal events and bleeding. This group of 
drugs appears to be engaged in the CKD population. 
Unfortunately, patients with CKD were specifically 
excluded from many trials comparing selective 
COX-2 inhibitor with non-selective NSAIDs, and 
as a result, the gastrointestinal protective effects of 
COX-2 inhibitors have not been demonstrated in 
patients with advanced CKD.13 
Selective COX-2 inhibitors appear to have 
a similar risk of reducing GFR and promoting 
adverse renal effects as compared with non-
selective NSAIDs. Selective COX-2 inhibitor may 
be more potent inducers of hypertension than non-
selective NSAIDs. Other adverse renal effects such 
as edema formation, hyponatremia, hyperkalemia, 
and metabolic acidosis are similar for selective 
COX-2 inhibitors and non-selective NSAIDs. 
Therefore, this drug should be prescribed with the 
13same attention as all kinds of other NSAIDs.  
On a case-control study in Canada to assess 
the association between NSAIDs exposure, 
including COX-2 inhibitors and the hospitalization 
for acute renal failure, acute renal failure is 
comparable to rofecoxib, naproxen, and non-
naproxen NSAIDs, but was borderline lower for 
15celecoxib.  
        4. Acetaminophen 
The National Kidney Foundation  
recommends acetaminophen as the non-narcotic 
analgesic option for patients with CKD. 
Acetaminophen has potent analgesic and 
antipyretic effects, but mild anti-inflammatory 
properties. Acetaminophen is a weak inhibitor of 
both COX-1 and COX-2 although the true 
mechanism of analgesia remains unknown. 
Acetaminophen is metabolized by the liver and does 
not require dose adjustment when used in CKD 
patients. There is no evidence that occasional use 
causes renal injury, but it has been suggested that 
very large doses for extended periods can cause 
papillary necrosis. When recommending 
acetaminophen to CKD patients, it is important to 
note is that many preparations contain a 
combination of acetaminophen with aspirin, 
NSAIDs and other potentially harmful ingredients. 
If acetaminophen are ineffective for pain control, 
nonacetylated salicylates (e.g. salsalate) may be an 
13option and can be recommended for CKD patients.  
On a case-control study in Sweden, the 
regular use of acetaminophen was associated with a 
gain of 2.5 in the risk of chronic renal failure, and the 
relative risk increased with increasing cumulative 
16lifetime doses.  
        5. Tramadol 
Tramadol, a centrally acting non-narcotic 
agent, is a potential alternative analgesic to 
NSAIDs, COX-2 inhibitors and acetaminophen for 
CKD patients. Tramadol acts on opioid receptors, 
has similar therapeutic and side-effect profile such 
as opioids, but without the same abuse potential. 
This drug also inhibits the reuptake of monoamines 
(norepinephrine and serotonin) by the nerve cells, 
which is believed to reduce central nervous system 
13pain sensing.  
Tramadol is metabolized in the liver and 
eliminated by the kidneys. The elimination half-life 
of 5 hours is unpredictably increased in patients 
with CKD and possibly up to two times longer. To 
avoid drug toxicity, it is reasonable to prescribe 
dosages that do not exceed 200 mg / day for CKD 
patients with a GFR less than 30 ml / min (CKD 
13stage 4 and 5).  
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13Table 3. Pain Medication Guidelines for Patients with CKD  
Pain Medication Guidelines for Patients with CKD
Determine the type, origin, and intensity of pain  
Determine level of kidney function by 24-hour urine or GFR estimate equations
Review medication list of  potential drug-drug interactions  
Attempt to take the least nephrotoxic medication; consider shorter -acting drugs 
with limited toxic metabolites and low interaction potential  
Generally begin therapy with a lower drug dose; adjust dose and interval based on 
level or stage of CKD
 
Increase compliance by informing patients
 
of expected efficacy and toxicity
Consider prophylaxis for known adverse effects
 Monitor medication levels if appropriate
 Reassess kidney function and requirement for pain medication on a regular basis
CONCLUSION
NSAIDs exert  anti- inflammatory,  
analgesic and anti-pyretic effects through the 
suppression of prostaglandin (PG), by inhibiting the 
enzyme cyclooxygenase (COX). Blockade of either 
or both of these enzymes can have different effects 
on renal function. However, both non-selective 
NSAID or selective NSAID often cause toxicity and 
renal abnormalities. The increased risk of renal 
impairment occurs in patients who regularly 
consume NSAIDs, advanced age, dehydration, 
impaired liver function, sepsis, multiple organ 
dysfunction, and critical illness in general. The 
mechanisms associated with NSAIDs use was 
altered intraglomerular hemodynamic and 
interstitial nephritis. Manifestations NSAID-
induced kidney disorders include sodium retention, 
edema, hypertension; hyperkalemia; papillary 
necrosis; acute renal failure; nephrotic syndrome; 
renal dysgenesis and worsening of CKD. NSAID 
use in patients with CKD should be appropriate 
indications, starting with the lowest effective dose 
and with close monitoring. 
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